Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1038/s41598-020-70143-6 http://scihub22266oqcxt.onion/10.1038/s41598-020-70143-6 32753646!7403393!32753646     free     free     free Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Sci+Rep 2020 ; 10 (1): 13093 Nephropedia Template TP {{tp|p=32753646|t=2020. In vitro screening of a FDA approved chemical library reveals potential inhibitors of SARS-CoV-2 replication |pdf=|usr=}}{{32753646}} gab.com Text In vitro screening of a FDA approved chemical library reveals potential inhibitors of SARS-CoV-2 replication JO: Sci Rep http://www.kidney.de/pget.php?&tw=1&pmid=32753646 #FOAvip A novel coronavirus, named SARS-CoV-2, emerged in 2019 in China and rapidly spread worldwide. As no approved therapeutics exists to treat COVID-19, the disease associated to SARS-Cov-2, there is an urgent need to propose molecules that could quickly enter into clinics. Repurposing of approved drugs is a strategy that can bypass the time-consuming stages of drug development. In this study, we screened the PRESTWICK CHEMICAL LIBRARY composed of 1,520 approved drugs in an infected cell-based assay. The robustness of the screen was assessed by the identification of drugs that already demonstrated in vitro antiviral effect against SARS-CoV-2. Thereby, 90 compounds were identified as positive hits from the screen and were grouped according to their chemical composition and their known therapeutic effect. Then EC50 and CC50 were determined for a subset of 15 compounds from a panel of 23 selected drugs covering the different groups. Eleven compounds such as macrolides antibiotics, proton pump inhibitors, antiarrhythmic agents or CNS drugs emerged showing antiviral potency with 2 < EC50 </= 20 microM. By providing new information on molecules inhibiting SARS-CoV-2 replication in vitro, this study provides information for the selection of drugs to be further validated in vivo. Disclaimer: This study corresponds to the early stages of antiviral development and the results do not support by themselves the use of the selected drugs to treat SARS-CoV-2 infection. Twit Text FOAVip In vitro screening of a FDA approved chemical library reveals potential inhibitors of SARS-CoV-2 replication ????Sci Rep http://www.kidney.de/pget.php?&tw=1&pmid=32753646 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32753646 #FOAvip English Wikipedia <ref>{{Cite pmid|32753646}}</ref> In vitro screening of a FDA approved chemical library reveals potential inhibitors of SARS-CoV-2 replication #MMPMID32753646 Touret F; Gilles M; Barral K; Nougairede A; van Helden J; Decroly E; de Lamballerie X; Coutard B Sci Rep 2020[Aug]; 10 (1): 13093 PMID32753646show ga A novel coronavirus, named SARS-CoV-2, emerged in 2019 in China and rapidly spread worldwide. As no approved therapeutics exists to treat COVID-19, the disease associated to SARS-Cov-2, there is an urgent need to propose molecules that could quickly enter into clinics. Repurposing of approved drugs is a strategy that can bypass the time-consuming stages of drug development. In this study, we screened the PRESTWICK CHEMICAL LIBRARY composed of 1,520 approved drugs in an infected cell-based assay. The robustness of the screen was assessed by the identification of drugs that already demonstrated in vitro antiviral effect against SARS-CoV-2. Thereby, 90 compounds were identified as positive hits from the screen and were grouped according to their chemical composition and their known therapeutic effect. Then EC50 and CC50 were determined for a subset of 15 compounds from a panel of 23 selected drugs covering the different groups. Eleven compounds such as macrolides antibiotics, proton pump inhibitors, antiarrhythmic agents or CNS drugs emerged showing antiviral potency with 2 < EC50 |Animals[MESH] |Antiviral Agents/chemistry/metabolism/pharmacology[MESH] |Betacoronavirus/isolation & purification/*physiology[MESH] |COVID-19[MESH] |Caco-2 Cells[MESH] |Cell Survival/drug effects[MESH] |Chlorocebus aethiops[MESH] |Coronavirus Infections/pathology/virology[MESH] |Drug Approval[MESH] |Drug Evaluation, Preclinical[MESH] |Drug Repositioning[MESH] |Humans[MESH] |Pandemics[MESH] |Pneumonia, Viral/pathology/virology[MESH] |SARS-CoV-2[MESH] |Small Molecule Libraries/*chemistry/metabolism/pharmacology[MESH] |Vero Cells[MESH]In vitro screening of a FDA approved chemical library reveals potentia(epmc).pdf DeepDyve Pubget Overpricing